

A Novel Dual PI3K and HDAC Inhibitor

Drug Name	***0043
Description	An inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K) is in clinical trials for the treatment of hematologic malignancies and solid tumors.
Target	HDAC; PI3K
Drug Modality	Small Molecule
Indication	Solid Tumor; Chronic Lymphocytic Leukemia; Lymphoma; Multiple Myeloma
Product Category	Signal Transduction Modulator
Mechanism of Action	Inhibiting the activities of HDAC and PI3K to induce tumor cells apoptosis
Status	Phase I
Patent	Granted

More Detail Available Upon Request

We look forward to hearing from you.